Previous 10 | Next 10 |
MINNEAPOLIS, MN / ACCESSWIRE / November 22, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announced that an abstract accepted for a Spotlight Poster presentation at the 2022 San Antonio Brea...
Celcuity Inc. (CELC) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Igor Gorbatchevsky - Chief Medical Officer Conference Call Participa...
MINNEAPOLIS, MN / ACCESSWIRE / November 10, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Cel...
Celcuity press release ( NASDAQ: CELC ): Q3 GAAP EPS of -$0.75 misses by $0.17 . Cash and cash equivalents of $57.5 million. For further details see: Celcuity GAAP EPS of -$0.75 misses by $0.17
Completed selection of 200 clinical trial sites for the Phase 3 VIKTORIA-1 breast cancer study; activated first clinical trial site in the third quarter; expect dosing of first patient by year-end Updated Phase 1b data will be reviewed during a Spotlight Poster Discussion Session at th...
MINNEAPOLIS, MN/ ACCESSWIRE / November 3, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced that it will release its financial results for the third quarter 2022 after the...
Seasoned executive brings over two decades of pharmaceutical business development and commercial strategy experience to Celcuity's Board of Directors MINNEAPOLIS, MN / ACCESSWIRE / September 14, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on develo...
Celcuity Inc. (CELC) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners, LLC Brian Sullivan - Co-Founder, Chairman & Chief Executive Officer Vicky Hahne - Chief Financial Officer Igor Gorbatch...
The following slide deck was published by Celcuity Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Celcuity Inc. 2022 Q2 - Results - Earnings Call Presentation
Celcuity press release ( NASDAQ: CELC ): Q2 GAAP EPS of -$0.55. At June 30, 2022, Celcuity had cash and cash equivalents of $66.9 million, compared to cash and cash equivalents of $84.3 million at December 31, 2021. For further details see: Celcuity GAAP EPS of -...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...